Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Calcified Tissue International
Published in: Calcified Tissue International 3/2000

01-03-2000

Histomorphometric Evaluation of the Recovering Effect of Human Parathyroid Hormone (1–34) on Bone Structure and Turnover in Streptozotocin-Induced Diabetic Rats

Authors: T. Tsuchida, K. Sato, N. Miyakoshi, T. Abe, T. Kudo, Y. Tamura, Y. Kasukawa, K. Suzuki

Published in: Calcified Tissue International | Issue 3/2000

Login to get access
Metadata
Title
Histomorphometric Evaluation of the Recovering Effect of Human Parathyroid Hormone (1–34) on Bone Structure and Turnover in Streptozotocin-Induced Diabetic Rats
Authors
T. Tsuchida
K. Sato
N. Miyakoshi
T. Abe
T. Kudo
Y. Tamura
Y. Kasukawa
K. Suzuki
Publication date
01-03-2000
Publisher
Springer-Verlag
Published in
Calcified Tissue International / Issue 3/2000
Print ISSN: 0171-967X
Electronic ISSN: 1432-0827
DOI
https://doi.org/10.1007/PL00005838

Other articles of this Issue 3/2000

Calcified Tissue International 3/2000 Go to the issue

BriefCommunication

Clinical Indications of Calcium-Phosphate Biomaterials and Related Composites for Orthopedic Procedures

OriginalPaper

Bone Mineral Density and Muscle Strength in Young Men with Mental Retardation (With and Without Down Syndrome)

OriginalPaper

Estrogen Deficiency is a Potential Cause for Osteopenia in Adult Male Patients with Noonan's Syndrome

OriginalPaper

Changes in Bone Turnover During the Menstrual Cycle in Cynomolgus Monkeys

OriginalPaper

Vitamin D and Estrogen Receptor Polymorphisms and Bone Mineral Changes in Postpartum Women

OriginalPaper

Genetic Variation and Covariation of Parathyroid Hormone Levels and Bone Density in the Human Population
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits